Synapse - Komal Jhaveri

Search Within

Komal Lachhman Jhaveri

Results (220)

Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)

Meeting Abstract

Jhaveri, K.; Hamilton, E.; Loi, S.; Schmid, P.; Darilay, A.; Gao, C.; Patel, G.; Wrona, M.; Andre, F.
Cancer Research (2021)

Fulltext@MSK | Save

Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Jhaveri, K.; Juric, D.; Varga, A.; Turner, N.; Schmid, P.; Saura, C.; Oliveira, M.; Krop, I. E.; Kalinsky, K.; Italiano, A.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Latest findings from the breast cancer cohort in SUMMIT - A phase 2 'basket' trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer

Meeting Abstract

Jhaveri, K.; Saura, C.; Guerrero-Zotano, A.; Spanggaard, I.; Bidard, F. C.; Goldman, J. W.; Garcia-Sáenz, J. A.; Cervantes, A.; Boni, V.; Crown, J.; more...
Cancer Research (2021)

Fulltext@MSK | Save

A phase I/Ib study evaluating GDC-0077 + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)

Meeting Abstract

Bedard, P. L.; Jhaveri, K.; Cervantes, A.; Gambardella, V.; Hamilton, E.; Italiano, A.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; more...
Cancer Research (2021)

Fulltext@MSK | Save

Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07)

Meeting Abstract

Andre, F.; Hamilton, E.; Loi, S.; Schmid, P.; Yu, T.; Lu, S.; Boston, S.; D'Cruz, C.; Herbolsheimer, P.; Jhaveri, K.
Cancer Research (2021)

Fulltext@MSK | Save

Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer

Journal Article

Ulaner, G. A.; Jhaveri, K.; Chandarlapaty, S.; Hatzoglou, V.; Riedl, C. C.; Lewis, J. S.; Mauguen, A.
Journal of Nuclear Medicine (2021)

Fulltext@MSK | Save

Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers

Journal Article

Jhaveri, K.; Chang, M. T.; Juric, D.; Saura, C.; Gambardella, V.; Melnyk, A.; Patel, M. R.; Ribrag, V.; Ma, C. X.; Aljumaily, R.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Meeting Abstract

Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Journal Article

Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
Nature Cancer (2020)

Fulltext@MSK | Save

Measuring tumor epichaperome expression using [(124)I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer

Journal Article

Jhaveri, K. L.; dos Anjos, C. H.; Taldone, T.; Wang, R.; Comen, E.; Fornier, M.; Bromberg, J. F.; Ma, W.; Patil, S.; Rodina, A.; more...
JCO Precision Oncology (2020)

Fulltext@MSK | Save